Literature DB >> 14705229

Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in pigmented villonodular synovitis suggests their potential role for joint destruction.

Mitsutoshi Uchibori1, Yoshihiro Nishida, Izuru Tabata, Hideshi Sugiura, Hiroatsu Nakashima, Yoshihisa Yamada, Naoki Ishiguro.   

Abstract

OBJECTIVE: Pigmented villonodular synovitis (PVNS) is an uncommon idiopathic, proliferative synovial disease. Since matrix metalloproteinases (MMP) are assumed to play an important role in the pathogenesis of PVNS, we examined the expression and activity of MMP and tissue inhibitor of metalloproteinases (TIMP) in PVNS.
METHODS: Synovial tissue samples were obtained from 10 patients with PVNS (knee 8, ankle 2) and 4 patients each with rheumatoid arthritis (RA) or osteoarthritis (OA) for comparison. Protein deposition and mRNA expression were determined by conventional immunohistochemical studies and reverse transcription-polymerase chain reaction (RT-PCR), respectively. Gelatin zymography was performed for detection of gelatin-degrading activity. The quantity of MMP and TIMP was measured by ELISA.
RESULTS: Intense immunostaining for MMP-1 was detected in both the multinucleated giant cells and mononuclear cells, whereas TIMP-1 was weakly positive. MMP-9 immunostained predominantly in the multinucleated cells, whereas other MMP and TIMP were weakly detected. RT-PCR analysis showed that mRNA expression of MMP-9 was stimulated in PVNS, whereas MMP-2 mRNA was not, compared to RA or OA. The gelatin zymogram indicated protease activities predominantly at 92 kDa and 67 kDa. In accord with the immunostaining results, the amount of MMP-1 and MMP-9 protein was significantly higher than that of TIMP-1 and MMP-2, respectively.
CONCLUSION: We characterized the expression and activity of MMP in PVNS and observed that PVNS tissues predominantly produce MMP-1 and MMP-9. Given that PVNS occasionally induces joint destruction, stimulated expression of MMP-1 and MMP-9 may contribute to the invasive activity and the bone and cartilage loss in PVNS.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14705229

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  6 in total

1.  Induction of host matrix metalloproteinases by Borrelia burgdorferi differs in human and murine lyme arthritis.

Authors:  Aruna K Behera; Ethan Hildebrand; Joanna Scagliotti; Allen C Steere; Linden T Hu
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

2.  Loss of extracellular matrix from articular cartilage is mediated by the synovium and ligament after anterior cruciate ligament injury.

Authors:  C M Haslauer; K A Elsaid; B C Fleming; B L Proffen; V M Johnson; M M Murray
Journal:  Osteoarthritis Cartilage       Date:  2013-09-13       Impact factor: 6.576

3.  Tenosynovial giant cell tumour (pigmented villonodular synovitis-)-like changes in periprosthetic interface membranes.

Authors:  Stephan Söder; Stefan Sesselmann; Thomas Aigner; Stephan Oehler; Abbas Agaimy
Journal:  Virchows Arch       Date:  2015-11-09       Impact factor: 4.064

4.  Expression of colony-stimulating factor 1 is associated with occurrence of osteochondral change in pigmented villonodular synovitis.

Authors:  Takehiro Ota; Hiroshi Urakawa; Eiji Kozawa; Kunihiro Ikuta; Shunsuke Hamada; Satoshi Tsukushi; Yoshie Shimoyama; Naoki Ishiguro; Yoshihiro Nishida
Journal:  Tumour Biol       Date:  2015-02-18

5.  Surgical treatment for diffused-type giant cell tumor (pigmented villonodular synovitis) about the ankle joint.

Authors:  Xingchen Li; Yang Xu; Yuan Zhu; Xiangyang Xu
Journal:  BMC Musculoskelet Disord       Date:  2017-11-14       Impact factor: 2.362

6.  Modified Lemaire extra-articular stabilisation of the knee for the treatment of anterolateral instability combined with diffuse pigmented villonodular synovitis: a case report.

Authors:  Cliodhna Farthing; Gernot Lang; Matthias J Feucht; Norbert P Südkamp; Kaywan Izadpanah
Journal:  BMC Musculoskelet Disord       Date:  2018-09-11       Impact factor: 2.362

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.